Patents by Inventor Juan R. Del Valle

Juan R. Del Valle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210008043
    Abstract: The present invention includes substituted chromenones that are useful to inhibit the IRE1/XBP-1 pathway. In certain embodiments, the compounds of the invention inhibit IRE1's RNase activity. In other embodiments, the compounds of the invention are useful to treat or prevent a cancer that involve activation of the ER stress response. The invention also relates, in certain aspects, to the discovery that secretory IgM (sIgM) can orchestrate an immunosuppressive microenvironment by recruiting myeloid-derived suppressor cells (MDSCs) into different tumor models, such as but not limited to solid tumors (such as but not limited to lung cancer) and tumors that have high levels of secreted IgM. In certain embodiments, sIgM produced by B cells or CLL cells can contribute to the accumulation of MDSCs in a tumor. In other embodiments, inhibition of the IRE1/XBP-1 pathway can ablate, minimize, or reduce MDSC levels in a tumor.
    Type: Application
    Filed: April 1, 2019
    Publication date: January 14, 2021
    Inventors: Chih-Chi Hu, Juan R. Del Valle
  • Patent number: 10738085
    Abstract: Disclosed herein are N-aminated variants of Gramicidin S and methods of using the same for treating infections in a subject.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: August 11, 2020
    Assignee: University of South Florida
    Inventors: Juan R. Del Valle, Lindsey Shaw
  • Patent number: 10730913
    Abstract: Disclosed herein are N-aminated variants of Gramicidin S and methods of using the same for treating infections in a subject.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: August 4, 2020
    Assignee: University of South Florida
    Inventors: Juan R. Del Valle, Lindsey Shaw
  • Publication number: 20200024247
    Abstract: Disclosed are XBP-1/IRE-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular B cell cancers, are also disclosed. Also disclosed is a genetic XBP-1-knockout cancer mouse model.
    Type: Application
    Filed: March 18, 2019
    Publication date: January 23, 2020
    Inventors: Juan R. Del Valle, Chih-Chi Andrew Hu
  • Patent number: 10507226
    Abstract: Disclosed herein are compounds comprising short N-aminated peptides and compositions comprising the same. The disclosed compounds and compositions maybe used in methods of inhibiting amyloid-beta aggregation and treating Alzheimer's disease.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: December 17, 2019
    Assignee: University of South Florida
    Inventor: Juan R. Del Valle
  • Patent number: 10351602
    Abstract: Disclosed herein are N-aminated variants of Gramicidin S and methods of using the same for treating infections in a subject.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 16, 2019
    Assignee: University of South Florida
    Inventors: Juan R. Del Valle, Lindsey Shaw
  • Patent number: 10323013
    Abstract: Disclosed are XBP-1/IRE-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular B cell cancers, are also disclosed. Also disclosed is a genetic XBP-1-knockout cancer mouse model. In still further aspects, the disclosed subject matter relates to methods for treating oncological and inflammatory disorders in a patient. For example, disclosed herein are methods whereby an effective amount of a compound or composition disclosed herein is administered to a patient having an oncological disorder, for example B-cell chronic lymphocytic leukemia (CLL), and who is in need of treatment thereof. XBP-1 deficiency causes leukemic cells to acquire phenotypes that are disadvantageous for their survival, such as compromised BCR signaling capability and increased surface expression of S1P1.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: June 18, 2019
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Juan R. Del Valle, Chih-Chi Andrew Hu
  • Publication number: 20160083361
    Abstract: Disclosed are XBP-1/IRE-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular B cell cancers, are also disclosed. Also disclosed is a genetic XBP-1-knockout cancer mouse model. In still further aspects, the disclosed subject matter relates to methods for treating oncological and inflammatory disorders in a patient. For example, disclosed herein are methods whereby an effective amount of a compound or composition disclosed herein is administered to a patient having an oncological disorder, for example B-cell chronic lymphocytic leukemia (CLL), and who is in need of treatment thereof. XBP-1 deficiency causes leukemic cells to acquire phenotypes that are disadvantageous for their survival, such as compromised BCR signaling capability and increased surface expression of S1 P1.
    Type: Application
    Filed: April 23, 2014
    Publication date: March 24, 2016
    Inventors: Juan R. Del Valle, Chih-Chi Andrew Hu